![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Orchestra BioMed Receives CE Mark for Implantable Hypertension Treatment
Orchestra BioMed Receives CE Mark for Implantable Hypertension Treatment
![](https://www.fdanews.com/ext/resources/test/Device_Images6/OrchestraBioMed_Logo.png?t=1567637436&width=430)
September 4, 2019
Orchestra BioMed has gained the CE Mark for its Moderato implantable pulse generator for treating hypertension while also serving as a pacemaker.
The system uses an implantable cardiac stimulation-based treatment for hypertension that immediately lowers the patient’s blood pressure while modulating the autonomic nervous system.
The principal investigator for the Moderato studies, Karl-Heinz Kuck, said the device has potential to be “a primary treatment” for hypertension.
Upcoming Events
-
21Oct